Tag Archives: pfizer

FTC Investigating Diabetes and Obesity Orange Book Patent Listings; Pfizer and Amarin Q1 ’24 Earnings Update

Three cardiometabolic-related news items have been observed: FTC has expanded its investigation targeting “junk patent listings” for Novo’s diabetes and weight loss drugs, among others (view press release); Pfizer hosted its Q1 ’24 earnings (press release; slides; infographic); and Amarin hosted its Q1 ’24 earnings call (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

New Insulin Patch Pump; Pfizer Q4 ‘23 Earnings; Lilly Initiates Ph2 LA Amylin Obesity Trial; Lilly Trying to Get Mounjaro Reimbursed in Germany

A series of cardiometabolic-related news items have been observed from Modular Medical, Pfizer, and Lilly. Below, FENIX provides highlights and insights for the respective news items, including thoughts on why the new patch pump from Modular Medical may be an acquisition/partnership target by Medtronic.

This content is for Read Less members only.
Already a member? Log in here

Pfizer Loses and Altimmune Wins with New Ph2 Obesity Data

Two cardiometabolic-related news items have been observed: Pfizer announced topline results from the danuglipron (BID oral GLP-1RA) Ph2b clinical trial and disclosed it will not be advancing the formulation into Ph3 (view press release); and Altimmune announced positive topline results from the Ph2 MOMENTUM study evaluating pemvidutide for the treatment of obesity (view press release). Following the results, Altimmune’s stock increased ~18%. Below, FENIX provides highlights and insights for the respective news items, including thoughts on how the Ph2b danuglipron data may impact Pfizer’s decision not to advance BID danuglipron.

This content is for Read Less members only.
Already a member? Log in here

Lilly Acquires Rights to Gene Editing Programs for CVD; Know Labs to Present at Bernstein CGM Disruptors Conference; Pharmacies Struggle to Afford GLP-1RAs; Sigrid Secures Funding for Diabetes/Obesity; Porosome Announces New T1DM/T2DM Treatment Approach; Pfizer and Amgen Q3 ’23 Earnings

A series of cardiometabolic-related news items have been observed from Lilly/Verve, Know Labs, Endpoints News, Sigrid Therapeutics, Porosome Therapeutics, Pfizer, and Amgen. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Altimmune Initiates Ph2b Pemvidutide NASH Trial; Pfizer, Esperion, and Merck Q2 ‘23 Earnings

Four cardiometabolic-related news items have been observed: Altimmune announced enrollment of the first subject in its Ph2b IMPACT trial evaluating the efficacy and safety of pemvidutide (QW GLP-1/GCG dual agonist) in NASH (view press release); and Pfizer (press release; slides), Esperion (press release; slides), and Merck (press release; slides) hosted their respective Q2 ‘23 earnings calls. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Abbott Q2 ’23 Earnings; Merck Initiates Ph3 Oral PCSK9i Program; Pfizer Partners with Riparian for CV Development; Amarin Corporate Updates; J&J Q2 ’23 Earnings

Five cardiometabolic-related news items have been observed from Abbott, Merck, Pfizer, Amarin, and Johnson & Johnson. Importantly, Abbott disclosed it is converting Libre 2 intermittent scanning CGMs into real-time CGMs through an app update, starting with the UK. Below, FENIX provides highlights and insights from the respective news items, including potential insight into Abbott’s rationale for the Libre 2 LCM initiative.

This content is for Read Less members only.
Already a member? Log in here

FENIX Analysis: Breaking Through Novo and Lilly’s Obesity Duopoly

With all of the (justified) hype surrounding the obesity market and the promising pipelines from a multitude of companies, a question has arisen regarding the potential of a new mega-partnership to compete with Novo Nordisk and Lilly. Below, FENIX provides thoughts and rationale on why CVRM history could repeat itself with a partnership between AstraZeneca and either Boehringer Ingelheim, Amgen, or Pfizer could be on the horizon. FENIX will also soon author a follow-up to this obesity partnership blast with a subsequent analysis discussing the rationale for why a Zealand acquisition could be an alternative option.

This content is for Read Less members only.
Already a member? Log in here

D&D Pharmatech Announces Positive Ph1 DD01 NAFLD Topline Results; FDA Clears NeuroBo’s IND for Ph2a DA-1241 NASH Trial; Pfizer Q1 ’23 Earnings

Three cardiometabolic-related news items have been observed: D&D Pharmatech announced positive topline results from its Ph1 SAD/MAD trial of DD01, a long-lasting dual GLP-1/glucagon receptor agonist, in overweight/obese patients with T2DM and NAFLD (view press release; CT.gov record); NeuroBo Pharmaceuticals announced FDA has cleared its IND application for DA-1241, a novel G-protein-coupled receptor 119 (GPR119) agonist (view press release); and Pfizer hosted its Q1 ’23 earnings call (view press release; slides) and provided a few GLP-1RA comments during Q&A. Below, FENIX provides highlights and insights into the respective news items. 

This content is for Read Less members only.
Already a member? Log in here